Toll-like receptor (TLR) mediated signalling induces pro-inflammatory responses and can 3 both suppress and exacerbate allergic responses in the airways. The aim of our study was to 4 directly compare the efficacy of different TLR agonists in inhibiting or exacerbating the 5 development of Th2-mediated responses in the airways and investigate if the suppressive 6 effects were associated with increased pro-inflammatory responses. Mice were immunized on 7 day 0, 14 and 21 by intraperitoneal injection of ovalbumin/alum and exposed to ovalbumin 8 aerosol on day 26 and 27. TLR2-, TLR3-, TLR4-, TLR7-and TLR9 agonists (0.001, 0.01, 9 0.1, or 1mg/kg) were administered intratracheally 1h before each allergen exposure. Both the 10 TLR7-and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 11 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg. The TLR2-and TLR4 12 agonists potentiated eosinophilia. All TLR agonists enhanced neutrophil numbers at doses as 13 low as 0.01 mg/kg, in particular TLR2-and TLR4 agonists. TLR7-and TLR9 agonists also 14 significantly reduced IL-4 and IL-5 levels and all TLR agonists, with the exception of TLR7, 15 enhanced the amount IL-1ß, IL-6, and TNF-α detected in the whole lung lavage. significantly only when TLR7 agonist was administered. When applied therapeutically 2 days 20 after allergen exposure, all TLR agonists, except TLR2, similarly reduced airway eosinophilia 21 and IL-4 levels. Taken together our results show that TLR7 agonists had the strongest anti-22 asthmatic effects with the lowest pro-inflammatory potential, suggesting that activating TLR7 23 may have the greatest potential to treat allergic disorders in humans. 24 3
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ABSTRACT 2
Toll-like receptor (TLR) mediated signalling induces pro-inflammatory responses and can 3 both suppress and exacerbate allergic responses in the airways. The aim of our study was to 4 directly compare the efficacy of different TLR agonists in inhibiting or exacerbating the 5 development of Th2-mediated responses in the airways and investigate if the suppressive 6 effects were associated with increased pro-inflammatory responses. Mice were immunized on 7 day 0, 14 and 21 by intraperitoneal injection of ovalbumin/alum and exposed to ovalbumin 8 aerosol on day 26 and 27. TLR2-, TLR3-, TLR4-, TLR7-and TLR9 agonists (0.001, 0.01, 9 0.1, or 1mg/kg) were administered intratracheally 1h before each allergen exposure. Both the 10 TLR7-and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 11 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg. The TLR2-and TLR4 12 agonists potentiated eosinophilia. All TLR agonists enhanced neutrophil numbers at doses as 13 low as 0.01 mg/kg, in particular TLR2-and TLR4 agonists. TLR7-and TLR9 agonists also 14 significantly reduced IL-4 and IL-5 levels and all TLR agonists, with the exception of TLR7, 15 enhanced the amount IL-1ß, IL-6, and TNF-α detected in the whole lung lavage. Only 16 application of TLR9 agonist induced detectable levels of IL-10 in the lung. Suppressive 17 effects of the TLR agonists were not dependent upon IFN-γ and IL-10 or associated with 18 increased numbers of Foxp3 + CD4
+ Tr cells in the lavage fluid. Airway resistance was reduced 19 significantly only when TLR7 agonist was administered. When applied therapeutically 2 days 20 after allergen exposure, all TLR agonists, except TLR2, similarly reduced airway eosinophilia 21 and IL-4 levels. Taken together our results show that TLR7 agonists had the strongest anti-22 asthmatic effects with the lowest pro-inflammatory potential, suggesting that activating TLR7 23 may have the greatest potential to treat allergic disorders in humans. 24 studies showing that TLR agonists, in particular endotoxins, promote the development of 1 asthma and that this effect is dependent on the dose administered [26] [27] [28] [29] [30] [31] . 2
The aim of our current study was to directly compare the effect of different TLR 3 agonists (TLR2: lipoteichonic acid; TLR3: Poly(I:C); TLR4: lipopolysaccharide; TLR7: 4 resiquimod; TLR9: CpG-oligodeoxynucleotides) on the development of asthmatic responses 5 in murine models of asthma. The most important question we wanted to answer was, which 6 TLR-agonist is most efficacious in reducing allergic responses at a dose where no or very 7 little innate inflammation is induced. We found that the different TLR agonists tested have 8 different suppressive effects on the development of Th2-responses and different 9 proinflammatory properties in the airways of mice and these depend on the dose and in which 10 setting they were used. Reduction of Th2 responses, with the exception of using a TLR7 11 agonist, was always associated with increased proinflammation. 
Materials and methods 2
TLR agonists 3
For activation of murine TLR2, TLR3, TLR4, TLR7 and TLR9 the respective agonists 4 were used; lipoteichonic acid from Staphylococcus aureus; LTA-SA, synthetic analog of 5 double stranded RNA; Poly(I:C), lipopolysaccharide from E.coli K12; LPS-EK, small 6 synthetic antiviral imidazoquinoline compound; R-848 and synthetic oligodeoxynucleotides 7 containing unmethylated CpG dinucleotides; ODN1826. All TLR-agonist were purchased 8 from InvivoGen, San Diego, USA. 9 10
Mice 11
Female C57Bl/6, IL10-/-deficient (C57Bl/6 background), and BALB/c mice were 12 purchased from Charles River (Sulzfeld, Germany). At the onset of the experiments, animals 13 were between 8 and 12 weeks of age and were kept in a pathogen-free animal facility. The 14 mice had free access to food and water. Care and use of experimental animals conformed to 15 the 'Guide for the Care and Use of Laboratory animals' published by the National Institute of 16 Health (NIH publication 85-23, revised 1985) , and the study was approved by the local 17 governing authority. 18 19
Treatment protocols 20
C57Bl/6, IL10-/-deficient (C57Bl/6 background) and BALB/c mice were sensitized 21 intraperitoneal (i.p.) with a mixture of 20 µg ovalbumin (Serva, Heidelberg, Germany) solved 22 in 100 µl phosphate buffered saline (PBS, Biowhittaker, Lonza, Verviers, Belgium) and 23 adsorbed to 100 µl Al(OH) 3 (Alum, Pierce, Rockford, USA). The total volume of 200 µl was 24 administered to animals on day 1, 14 and 21. Mice were exposed to 1% ovalbumin or PBS 25 aerosol on two consecutive days (day 26 and day 27) for 20 min. In the protective models 26 0.001, 0.01, 0.1, and 1.0 mg/kg of TLR2-, TLR3-, TLR4-, TLR7-or TLR9 agonists 1 (InvivoGen, San Diego, USA) per mouse was solved in 50 µl PBS and administered 2 intratracheal (i.tr.) 1 h before each ovalbumin exposure (Fig. 1A ) or 1 mg/kg 4 days prior to 3 allergen exposure (Fig. 1B) . In the therapeutic model 1 mg/kg of respective TLR agonist was 4 administered intratracheal on day 29 followed by an additional ovalbumin exposure on day 33 5 (Fig. 1C) . Mice were sacrificed 24 h after the last ovalbumin exposure. Vehicle controls were 6 sensitized intraperitoneal with PBS and Alum, and were exposed to PBS aerosol. 
2.6
Detection of Cytokines by ELISA and multiplex technology 1 In the protective model (Fig. 1A) amount of cytokines and chemokines in the whole 2 lung lavage fluid were determined using the 96 well plate mouse cytokine/chemokine 3 premixed multiplex lincoplex KIT assay (LINCO, St. Charles, USA) according to the 4 manufactures instructions. In brief, fluorescently labeled microspheres coated with cytokine-5 specific capture mAbs were incubated overnight at 2-8° C with 25 µl of whole lung lavage. 6
After two washing steps, biotinylated detection mAbs were added and incubated for 60 min at 7 room temperature, followed by 30 min of incubation with streptavidin-phycoerythrin. After 8 three washing steps sheath fluid was added and the plates were analyzed using a Bio-Plex 9 reader (Bio-Rad, München, Germany). Standard curves and concentrations were calculated 10 with BioPlex Manager 3.0 software. In preventive and therapeutic models amounts of IL-4 11 and IL-5 in the whole lung lavage were measured by standard ELISA, using BD Biosciences 12 mouse IL-4 and BD Biosciences mouse IL-5 ELISA sets (BD Biosciences, San Diego, USA) 13 according to the manufactures instructions for detection. 14 15 2. 7 Histological analysis 16 Lungs were prepared 24 h after the last TLR ovalbumin exposure. Lungs were fixed in 17 4% phosphate-buffered formalin for 24 h and embedded in paraffin wax. Sections (2-3 µm) 18 were cut and stained using standard histological protocols with haematoxylin and eosin 19 Dried aerosols were generated by a computer-controlled, jet-driven aerosol generator system 9 (particle size 2.8 µm MMAD; Bronchy III, Fraunhofer ITEM, licensed by Buxco, Troy, NY, 10 USA). Aerosol concentrations were determined by a gravimetrically calibrated photometer. 11
The total dose inhaled via the orotracheal tube in µg was calculated and controlled by a 12 
Results 14
Effects of TLR agonists in a preventive setting on the development of allergic 15 inflammation in the lungs 16 17
The pro-inflammatory and anti-asthmatic effects of five different TLR agonists were 18 tested in a preventive model for allergic asthma in mice. For this purpose, doses of 0.001, 19 0.01, 0.1 and 1.0 mg/kg of TLR2-, TLR3-, TLR4-, TLR7-and TLR9 agonists were given 20 intratracheal one hour before each allergen exposure (Fig. 1A) . We then analyzed which TLR 21 agonists induced the strongest influx of macrophages and neutrophils and which had the 22 strongest inhibitory effect on the development of airway-eosinophilia. In our model a very 23 strong eosinophilia is induced. However, a weak neutrophilia is also present. How the 24 neutrophilia impacts on lung pathology is not known. Based on publications showing that the 25 presence of neutrophils correlates with impaired lung function, we suggest that the neutrophils 26 together with the eosinophils may contribute to the increased AHR after MCH challenge in 1 the OVA treated and challenged mice. Figure 2 shows that all agonists, with the exception of 2 TLR7 agonist, dose dependently increased the amounts of total macrophages found in the 3 whole lung lavage. A similar effect was seen on the recruitment of neutrophils into the lung. 4
Interestingly, administration of TLR7 agonist also induced a very weak neutrophilia, at a dose 5 of 0.1mg/kg. Surprisingly, compared to other published reports [12;17;24;25], we found that 6 only TLR3-, TLR7-, and TLR9 agonists suppressed the development of allergen induced 7 airway eosinophilia. In contrast, we detected a significant increase in the recruitment of 8 eosinophils when lower doses of either TLR2-or TLR4 agonists were used. Histological 9 analysis confirmed the overall lower inflammation detected in the TLR3-, TLR7-and TLR9 10 agonist treated mice in comparison to the ovalbumin controls and TLR2-and TLR4 agonist 11 treated animals which showed the strongest inflammation (Fig. 3) . 12
All tested agonists, again with the exception of TLR7, induced the production of the 13 pro-inflammatory cytokines and chemokines IL-6, IL-1ß, TNF-α and reduced the levels of 14 IL-4 and IL-5 in the whole lung lavage (Fig. 4) . Most of the observed effects were dose 15 dependent. Interestingly, we found that TLR9 agonist was the only agonist inducing the 16 production of IL-10. IL-13 was also reduced in the mice treated with agonists TLR9, TLR7, 17 TLR4 and TLR2 and no difference in the amount of IFN-γ was found in any of the ovalbumin 18 treated groups (data not shown). IL-12 and IFN-α and -ß could not be detected in any of the 19 whole lung lavage samples. When the TLR agonists were administered alone and the animals 20
were not treated with ovalbumin enhanced IL-6, IL-1 ß, and TNF-α levels were also detected 21 in the whole lung lavage (data not shown). 22
We also analyzed which of the TLR agonists had suppressive effects on the 23 development of AHR. Figure 5 shows that only the TLR7 agonist significantly reduced AHR. 24
Both TLR2-and TLR4 agonists have been shown to be able to reduce airway 25 eosinophilia in mice [17;24;25]. We did not see this effect. However, this may be due todifferent protocols used. For this reason we also administered the different TLR agonist 1 intratracheal at the highest dose, once, 4 days before the allergen exposure (Fig. 1B) . We 2 found that in this experimental setting all of the TLR agonists inhibited the development of 3 airway eosinophilia. No significant increase in neutrophil numbers was detected and TLR4 4 agonist was the only TLR agonist that induced a significant increase in macrophage numbers 5 at this time point. The lack of neutrophilia was somewhat surprising, since we observed a 6 strong neutrophilia in the airways, when the TLR agonists were administered directly before 7 the allergen challenge (Figure 2. ). The most likely explanation for this finding is that in all 8 cases a neutrophilia is induced, however, at the later time-point no longer detectable. 9
Supporting this view are kinetic studies showing that the maximum neutrophilia in the lung is 10 observed 24h after TLR application and no or few neutrophils are present 5 days after the 11 application (data not shown). TLR2-, TLR3-, and TLR4 agonists also reduced IL-4 and IL-5 12 levels whereas TLR9 agonists only reduced IL-4 levels in the whole lung lavage ( Figure 6B) . 13
Interestingly, the TLR-4 and TLR9 agonist treated mice also showed reduced AHR (Fig. 6C) Figure 1A in IL-10 deficient mice on a C57Bl/6 background using the 22 three agonists, which showed a significant reduction in Th2 responses in the lung. Figure 7A  23 shows that the suppressive effects of the three tested TLR agonists were similar in both the 24 control and IL-10 deficient mice. Furthermore, treating ovalbumin immunised/exposed and 25 antibodies showed that the suppressive effects appeared not to be dependent upon either IFN-1 γ or IL-10 (Fig. 7B) . We also analyzed if increased numbers of Foxp3 + Tr cells could be 2 found in the whole lung lavage of ovalbumin and TLR agonist treated mice. Figure 8 shows 3 that the suppressive effects of TLR3-, TLR7-and TLR9 agonist were not associated with 4 increased numbers of FoxP3 + CD4 + T cells in the whole lung lavage. Interestingly, both 5 TLR2-and TLR4 agonists treated mice showed increased numbers of Tr cells in the whole 6 lung lavage, albeit without reducing the overall numbers of eosinophils. Surprisingly we 7 found strongly reduced numbers of FoxP3 + CD4 + and CD4 + T cells in the whole lung lavage of 8 TLR7 agonist treated mice. 9 10
TLR agonist mediated suppression of allergen-induced eosinophilia in a therapeutic 11 setting 12
The experiments above clearly show that some but not all of the tested TLR-agonists 13 reduced the development of allergen-induced Th2-responses in the lung when administered 14 before allergen exposure. In this experimental preventive setting no lung inflammation has 15 occurred prior to the treatment with the TLR agonists (data not shown). For this reason we 16 also analyzed the effects of the different TLR agonists in a therapeutic setting where the TLR 17 agonists were administered intratracheal 2 days after the second ovalbumin exposure (day 30) 18 followed by a final allergen-exposure on day 33 (Fig. 1C) . For these experiments we used the 19 dose which had the greatest suppressive effect in the protective model. Figure 9A shows that 20 all the TLR agonists with the exception of the TLR2 agonist significantly reduced the 21 development of airway eosinophilia. No increase in neutrophil numbers was observed in any 22 of the treated mice. However, TLR4 agonist treated mice showed a significant increase in 23 total macrophage numbers. All TLR agonists reduced IL-4 levels in the whole lung lavage. 24 IL-5 levels were also significantly reduced (with the exception of the TLR4 agonist treated 25 mice). 26 
Discussion 2
The aim of this study was to determine the efficacy of different TLR agonists in 3 suppressing the development of Th2-mediated responses in the airways and to investigate if 4 the suppressive effects were associated with increased pro-inflammatory responses. We found 5 that when the different agonists were administered intratracheally 1h before allergen exposure 6 (preventive setting) TLR9-, TLR7-, and TLR3 agonists dose dependently suppressed the 7 development of allergen induced airway eosinophilia, and IL-4 and IL-5 levels detected in the 8 whole lung lavage. These findings are in unison with previously published reports 9 [10;13;14;22]. With the exception of TLR7 agonist all the agonists, dose dependently 10 increased the amounts of total macrophages, neutrophils and pro-inflammatory cytokines 11 found in the whole lung lavage. The stronger the inflammatory response induced by TLR9-12 and TLR3 agonist, the stronger the suppressive effect on the development of allergen-induced 13 Th2-mediated responses. TLR7 agonist showed only a weak induction of a pro-inflammatory 14 response but was the only agonist found to significantly reduce AHR. In contrast to other 15 published reports [12;17;24;25] we found that application of TLR4-or TLR2 agonist did not 16 suppress the development of allergen induced Th2-responses in the lung or AHR. However, 17 this may be due to different protocols used. Supporting this view was our finding that when 18 we administered the different TLR agonist intratracheal at the highest dose once 4 days before 19 the allergen exposure, all of the TLR agonists inhibited the development of airway 20 eosinophilia. This clearly suggests that the effects of TLR4-and TLR2 agonist depend on the 21 time point of application. Supporting this view was our finding that under these conditions the 22 TLR4-and now also the TLR9 agonists reduced AHR, an effect not seen when they were 23 administered directly before allergen challenge. Surprisingly, the TLR7 agonist which showed 24 a protective effect on AHR given directly before allergen challenge, no longer had an effect 25 under these conditions. This shows that the protective effects of different TLR agonists on 1 AHR strongly depend on the time they were administered in respect to allergen challenge. however, we could not detect IFN-α or -ß in the whole lung lavage suggesting that these may 23 not be responsible for the suppression of the allergic response. We cannot rule out the 24 possibility that they were induced in too small an amount to be detected by ELISA. Theinduction of regulatory T cells (Tr) has also been hypothesized in TLR agonist mediated 1 suppression of allergic disorders [23;34;35] . However, in our experiments CD4 + FoxP3 + T cell 2 numbers in the whole lung lavage did not increase in the groups which showed reduced 3 allergic responses. Interestingly, Tr numbers were increased in the TLR4-and TLR2 agonist 4 treated mice, which showed no reduced allergic response when administered directly before 5 the allergen-exposure. 6
Currently, we cannot answer the question by which mechanism the different TLR 7 agonists mediate their suppressive effects, however TLR7 agonists may have a different mode 8 of action than the TLR9-and TLR3 agonists. We found, that the TLR7 agonist treated mice 9 had a strong reduction in total CD4 + T cell numbers in the whole lung lavage. This suggests 10 that TLR7 agonist treatment may lead to a loss or lack of recruitment of CD4 + cells into the 11 lung, thus explaining the reduced Th2-responses detected in the airways. Supporting this view 12 is the previously published report that the TLR7 agonist R-848, which we also used for our 13 study, leads to a lymphopenia [36] . This would also possibly explain why the weak 14 proinflammation detected in the TLR7-agonist treated mice was associated with suppressed 15 Th2-responses in our model. If this is a general effect of a TLR7 agonist or an off-target effect 16 of R-848 needs to be determined. 17
When treating patients with atopic asthma, with the exception of seasonal asthma, all 18 patients will have ongoing Th2 type inflammation in the airways [1] . In respect to possible 19 future use in humans, we also analyzed the effects of the different TLR agonists in a 20 therapeutic setting. In this setting the TLR agonists were administered after the allergic 21 inflammation in the lung has already occurred. We found that all TLR agonists with the 22 exception of TLR2 significantly reduced the development of airway eosinophilia and IL-4 23 levels in the whole lung lavage. No increase in numbers of neutrophils was observed. This 24 suggests that TLR agonists may also be used to treat patients with established allergic 1 inflammation in the airways. 2
Previous reports suggest that infections and the application of TLR agonists can also 3 exacerbate allergic responses, in particular TLR4-and TLR2 agonist LPS and LTA-SA [26-4 29]. We also found some evidence that TLR agonists increased the allergic Th2 response. At 5 low doses both TLR4-and TLR2 agonist significantly increased allergen-induced recruitment 6 of eosinophils into the airways when administered directly into the lung before allergen 7
exposure. This supports the hypothesis, that some TLR agonist can also increase allergic 8 responses, in particular, when low doses are administered. This also needs to be taken into 9 account when patients are to be treated. 10
In conclusion, we found that the TLR2-, TLR3-, TLR4-, TLR7-, and TLR9 agonists 11 have different suppressive effects on the development of Th2-mediated responses in the 12 airways. These depend on the dose and at which point in time, in respect to allergen exposure, 13 they were given e.g. one day or 4 days before allergen challenge or in a therapeutic setting 14 after allergen challenge. All the tested agonists induced airway neutrophilia and with the 15 exception of TLR7 agonists increased the amounts of pro-inflammatory cytokines in the 16 airways, albeit to different degrees, when directly administered into the lung. This raises the 17 question if any of the tested TLR agonists are safe for human use when repeatedly 18 administered directly into the lung. In particular TLR2-and TLR4 agonists which showed a 19 severe inflammation in the lungs as detected by histology and the presence of large numbers 20 of neutrophils in the lung lavage. However, the TLR7 agonists showed only a weak pro 21 inflammatory potential and a high anti-allergic effect, suggesting that a TLR7 agonist may be 22 
